IONS IONIS PHARMACEUTICALS INC Product Launches 8-K Filing 2024 - Positive Results from Phase 3 Study Ionis Pharmaceuticals announced positive results from Phase 3 study of olezarsen for the treatment of adults with familial chylomicronemia syndrome (FCS).Get access to all SEC 8-K filings of the IONIS PHARMACEUTICALS INC